|
1
|
Baffy G, Brunt EM and Caldwell SH:
Hepatocellular carcinoma in non-alcoholic fatty liver disease: An
emerging menace. J Hepatol. 56:1384–1391. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Costantini S, Di Bernardo G, Cammarota M,
Castello G and Colonna G: Gene expression signature of human HepG2
cell line. Gene. 518:335–345. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Combs SE, Habermehl D, Ganten T, Schmidt
J, Edler L, Burkholder I, Jäkel O, Haberer T and Debus J: Phase i
study evaluating the treatment of patients with hepatocellular
carcinoma (HCC) with carbon ion radiotherapy: The PROMETHEUS-01
trial. BMC Cancer. 11:672011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Colagrande S, Inghilesi AL, Aburas S,
Taliani GG, Nardi C and Marra F: Challenges of advanced
hepatocellular carcinoma. World J Gastroenterol. 22:7645–7659.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yeo W, Mok TS, Zee B, Leung TW, Lai PB,
Lau WY, Koh J, Mo FK, Yu SC, Chan AT, et al: A randomized phase III
study of doxorubicin versus cisplatin/interferon
alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy
for unresectable hepatocellular carcinoma. J Natl Cancer Inst.
97:1532–1538. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Leung TW, Tang AM, Zee B, Yu SC, Lai PB,
Lau WY and Johnson PJ: Factors predicting response and survival in
149 patients with unresectable hepatocellular carcinoma treated by
combination cisplatin, interferon-alpha, doxorubicin and
5-fluorouracil chemotherapy. Cancer. 94:421–427. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Di Maio M, Daniele B, Pignata S, Gallo C,
De Maio E, Morabito A, Piccirillo MC and Perrone F: Is human
hepatocellular carcinoma a hormone-responsive tumor? World J
Gastroenterol. 14:1682–1689. 2008. View Article : Google Scholar
|
|
8
|
Toledo M, Penna F, Oliva F, Luque M,
Betancourt A, Marmonti E, López-Soriano FJ, Argilés JM and Busquets
S: A multifactorial anti-cachectic approach for cancer cachexia in
a rat model undergoing chemotherapy. J Cachexia Sarcopenia Muscle.
7:48–59. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Loberg RD, Bradley DA, Tomlins SA,
Chinnaiyan AM and Pienta KJ: The lethal phenotype of cancer: The
molecular basis of death due to malignancy. CA Cancer J Clin.
57:225–241. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sedlacek SM: An overview of megestrol
acetate for the treatment of advanced breast cancer. Semin Oncol.
15 (2 Suppl 1):S3–S13. 1988.
|
|
11
|
Bines J, Dienstmann R, Obadia RM, Branco
LG, Quintella DC, Castro TM, Camacho PG, Soares FA and Costa ME:
Activity of megestrol acetate in postmenopausal women with advanced
breast cancer after nonsteroidal aromatase inhibitor failure: A
phase II trial. Ann Oncol. 25:831–836. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sharma D, Subbarao G and Saxena R:
Hepatoblastoma. Semin Diagn Pathol. 34:192–200. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang K and Chow PK: The effect of
megestrol acetate on growth of HepG2 cells in vitro and in vivo.
Clin Cancer Res. 10:5226–5232. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Villa E, Moles A, Ferretti I, Buttafoco P,
Grottola A, Del Buono M, De Santis M and Manenti F: Natural history
of inoperable hepatocellular carcinoma: Estrogen receptors' status
in the tumor is the strongest prognostic factor for survival.
Hepatology. 32:233–238. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Douer D and Tallman MS: Arsenic trioxide:
New clinical experience with an old medication in hematologic
malignancies. J Clin Oncol. 23:2396–2410. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kito M, Akao Y, Ohishi N, Yagi K and
Nozawa Y: Arsenic trioxide-induced apoptosis and its enhancement by
buthionine sulfoximine in hepatocellular carcinoma cell lines.
Biochem Biophys Res Commun. 291:861–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chiu HW, Tseng YC, Hsu YH, Lin YF, Foo NP,
Guo HR and Wang YJ: Arsenic trioxide induces programmed cell death
through stimulation of ER stress and inhibition of the
ubiquitin-proteasome system in human sarcoma cells. Cancer Lett.
356:762–772. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kang YH and Lee SJ: The role of p38 MAPK
and JNK in Arsenic trioxide-induced mitochondrial cell death in
human cervical cancer cells. J Cell Physiol. 217:23–33. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu D, Wang ZH and Zhu LY: Mechanism of
arsenic trioxide-induced apoptosis in hepatic blastoma cells HepG2.
Zhonghua Zhong Liu Za Zhi. 25:120–123. 2003.PubMed/NCBI
|
|
20
|
Schaeffer HJ and Weber MJ:
Mitogen-activated protein kinases: Specific messages from
ubiquitous messengers. Mol Cell Biol. 19:2435–2444. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kyriakis JM and Avruch J: Mammalian MAPK
signal transduction pathways activated by stress and inflammation:
A 10-year update. Physiol Rev. 92:689–737. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang SH, Sharrocks AD and Whitmarsh AJ:
MAP kinase signalling cascades and transcriptional regulation.
Gene. 513:1–13. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sui X, Kong N, Ye L, Han W, Zhou J, Zhang
Q, He C and Pan H: p38 and JNK MAPK pathways control the balance of
apoptosis and autophagy in response to chemotherapeutic agents.
Cancer Lett. 344:174–179. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Peluso I, Yarla NS, Ambra R, Pastore G and
Perry G: MAPK signalling pathway in cancers: Olive products as
cancer preventive and therapeutic agents. Semin Cancer Biol.
2017.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lin CC, Hsu C, Hsu CH, Hsu WL, Cheng AL
and Yang CH: Arsenic trioxide in patients with hepatocellular
carcinoma: A phase II trial. Invest New Drugs. 25:77–84. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yu Z, Wu F, Chen L, Li Q, Wang C, Dong J
and Xie SQ: ETME, a novel β-elemene derivative, synergizes with
arsenic trioxide in inducing apoptosis and cell cycle arrest in
hepatocarcinoma cells via a p53-dependent pathway. Acta Pharm Sin
B. 4:424–429. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhai B, Jiang X, He C, Zhao D, Ma L, Xu L,
Jiang H and Sun X: Arsenic trioxide potentiates the anti-cancer
activities of sorafenib against hepatocellular carcinoma by
inhibiting Akt activation. Tumour Biol. 36:2323–2334. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li W, Wang M, Wang L, Ji S, Zhang J and
Zhang C: Icariin synergizes with arsenic trioxide to suppress human
hepatocellular carcinoma. Cell Biochem Biophys. 68:427–436. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jiang H, Ma Y, Chen X, Pan S, Sun B,
Krissansen GW and Sun X: Genistein synergizes with arsenic trioxide
to suppress human hepatocellular carcinoma. Cancer Sci.
101:975–983. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lopez-Terrada D, Cheung SW, Finegold MJ
and Knowles BB: Hep G2 is a hepatoblastoma-derived cell line. Hum
Pathol. 40:1512–1515. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chong Y, Zhang J, Guo X, Li G, Zhang S, Li
C, Jiao Z and Shao M: MicroRNA-503 acts as a tumor suppressor in
osteosarcoma by targeting L1CAM. PLoS One. 9:e1145852014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kitagawa Y, Ueda M, Ando N, Ozawa S and
Kitajima M: Effect of endogenous and exogenous EGF on the growth of
EGF receptor-hyperproducing human squamous cell carcinoma implanted
in nude mice. Br J Cancer. 72:865–868. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Choudhary GS, Al-Harbi S and Almasan A:
Caspase-3 activation is a critical determinant of genotoxic
stress-induced apoptosis. Methods Mol Biol. 1219:1–9. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Eguchi R, Fujimori Y, Takeda H, Tabata C,
Ohta T, Kuribayashi K, Fukuoka K and Nakano T: Arsenic trioxide
induces apoptosis through JNK and ERK in human mesothelioma cells.
J Cell Physiol. 226:762–768. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mao J, Yang J, Zhang Y, Li T, Wang C, Xu
L, Hu Q, Wang X, Jiang S, Nie X and Chen G: Arsenic trioxide
mediates HAPI microglia inflammatory response and subsequent neuron
apoptosis through p38/JNK MAPK/STAT3 pathway. Toxicol Appl
Pharmacol. 303:79–89. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Villa E, Ferretti I, Grottola A, Buttafoco
P, Buono MG, Giannini F, Manno M, Bertani H, Dugani A and Manenti
F: Hormonal therapy with megestrol in inoperable hepatocellular
carcinoma characterized by variant oestrogen receptors. Br J
Cancer. 84:881–885. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chao Y, Chan WK, Wang SS, Lai KH, Chi CW,
Lin CY, Chan A, Whang-Peng J, Lui WY and Lee SD: Phase II study of
megestrol acetate in the treatment of hepatocellular carcinoma. J
Gastroenterol Hepatol. 12:277–281. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chow PK, Machin D, Chen Y, Zhang X, Win
KM, Hoang HH, Nguyen BD, Jin MY, Lobo R, Findlay M, et al:
Randomised double-blind trial of megestrol acetate vs placebo in
treatment-naive advanced hepatocellular carcinoma. Br J Cancer.
105:945–952. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Farrar DJ: Megestrol acetate: Promises and
pitfalls. AIDS Patient Care STDS. 13:149–152. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Siu KP, Chan JY and Fung KP: Effect of
arsenic trioxide on human hepatocellular carcinoma HepG2 cells:
Inhibition of proliferation and induction of apoptosis. Life Sci.
71:275–285. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chan JY, Siu KP and Fung KP: Effect of
arsenic trioxide on multidrug resistant hepatocellular carcinoma
cells. Cancer Lett. 236:250–258. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Oketani M, Kohara K, Tuvdendorj D,
Ishitsuka K, Komorizono Y, Ishibashi K and Arima T: Inhibition by
arsenic trioxide of human hepatoma cell growth. Cancer Lett.
183:147–153. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Song J, Zhao Z, Fan X, Chen M, Cheng X,
Zhang D, Wu F, Ying X and Ji J: Shikonin potentiates the effect of
arsenic trioxide against human hepatocellular carcinoma in vitro
and in vivo. Oncotarget. 7:70504–70515. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yang X, Sun D, Tian Y, Ling S and Wang L:
Metformin sensitizes hepatocellular carcinoma to arsenic
trioxide-induced apoptosis by downregulating Bcl2 expression.
Tumour Biol. 36:2957–2964. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ling S, Xie H, Yang F, Shan Q, Dai H, Zhuo
J, Wei X, Song P, Zhou L, Xu X and Zheng S: Metformin potentiates
the effect of arsenic trioxide suppressing intrahepatic
cholangiocarcinoma: Roles of p38 MAPK, ERK3 and mTORC1. J Hematol
Oncol. 10:592017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Mandegary A, Torshabi M, Seyedabadi M,
Amirheidari B, Sharif E and Ghahremani MH: Indomethacin-enhanced
anticancer effect of arsenic trioxide in A549 cell line:
Involvement of apoptosis and phospho-ERK and p38 MAPK pathways.
Biomed Res Int. 2013:2375432013. View Article : Google Scholar : PubMed/NCBI
|
